Sermorelin Monitoring Schedule, Labs & Exams

HealthRX.com

No standard sermorelin lab schedule exists today

14 daysLength of each dosing period in the adult study of older menSource: pubmed.ncbi.nlm.nih.gov

Print or save as PDF

Key numbers

  • 30 micrograms per kgDose given to prepubertal children in the 1-year pediatric trial (not a current recommendation)Source: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • 8.0 cm/yrMean height velocity at 6 months in prepubertal children, up from 4.1 cm/yr at baselineSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • 3 to 6 monthsInterval for tracking height velocity, bone age and safety chemistry in the pediatric trialSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • 14 daysLength of each dosing period in the adult study of older menSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026

See the public record for Sermorelin

  • Approval status / No FDA-approved sermorelin product; Geref approvals withdrawn 2009 [1]
  • Pediatric tracking / Height velocity, bone age, safety chemistry every 3 to 6 months [2]
  • Pediatric labs reported / No change in fasting glucose; IGF-I not excessively raised [2]
  • Pediatric dose studied / 30 micrograms per kg at bedtime; not a current recommendation [2]
  • Adult data / IGF-I and 24-hour GH profiles during 14-day dosing in 10 older men [3]
  • IGF-I assay caveat / Assay performance and comparability need improvement; age-specific ranges recommended [4]

Where a monitoring schedule would come from

Sermorelin's only FDA approvals belonged to Geref: a diagnostic test of the pituitary's ability to secrete growth hormone, and treatment of idiopathic growth hormone deficiency in children with growth failure [1]. The manufacturer discontinued Geref in 2008 and FDA withdrew both approvals in 2009, later determining that it was not withdrawn from sale for reasons of safety or effectiveness [1]. Geref was never approved for adults, anti-aging, weight loss or athletic performance [1].

Compounded sermorelin is not FDA-approved, and FDA does not review its safety, effectiveness, or quality before marketing [5].

What people on Reddit report

People on sermorelin describe ordering their own IGF-1 labs, insurance coverage, and how they read IGF-1 results against reference ranges.

ZankesQ · USPeptides

I ordered IGF-1 labs myself. I checked with my health insurance first. They wouldn't cover it, though some might.

Reports ordering IGF-1 labs personally after insurance would not cover them.

Read the source discussion

lifeforever44 · USPeptides

I cannot put an exact number on it, but once IGF-1 starts getting very high, like 600+ on bloodwork, that is where I would be more cautious about unwanted side effects.

Says there is no exact cutoff and that very high IGF-1 on bloodwork is the point for more caution.

Read the source discussion

EconomistOk5506 · USPeptides

Your 225 IGF-1 is already in the upper-middle of the range for your age, which is pretty good. Sermorelin will likely push you toward the upper end (250-290+) but the body composition benefits scale with the increase, not just the absolute number.

Argues that body composition gains follow the size of the rise, not a fixed target number.

Read the source discussion

Questions worth asking

Choose the questions you want to keep

What the 1-year pediatric trial monitored

The Geref International Study Group trial, published in the Journal of Clinical Endocrinology and Metabolism in 1996, enrolled 110 previously untreated prepubertal children with growth hormone deficiency, 86 of them evaluable for efficacy, given 30 micrograms per kg subcutaneously at bedtime for up to 1 year [2]. Height velocity, bone age progression, and safety measures including clinical chemistry were monitored every 3 to 6 months [2].

Mean height velocity rose from 4.1 cm/yr at baseline to 8.0 cm/yr at 6 months and 7.2 cm/yr at 12 months [2]. The study reported no adverse changes in general biochemical or hormonal analyses, no change in fasting glucose, no excessive generation of IGF-I, and good overall tolerability [2].

What the adult study measured

Ten healthy older men (mean age 68) took 0.5 mg and 1 mg GHRH(1-29) subcutaneously twice daily for 14 days each, in random order, compared with nine younger men [3]. IGF-I and 24-hour growth hormone profiles were measured at baseline and on day 14 of each dose; after the 1 mg dose, these measures were not significantly different from the younger men [3]. This was a short physiology study of hormone levels, not a trial of long-term adult monitoring or of a target IGF-I range.

Assay caveat and sport status

A 2011 consensus statement from representatives of the Growth Hormone Research Society, the IGF Society and the IFCC concluded that major improvements are needed in GH and IGF-I assay performance and comparability. It recommended a commutable standard for each assay and age-specific normative data for IGF-I [4].

WADA's 2026 Prohibited List names sermorelin in S2.2.4 (growth hormone releasing factors), prohibited at all times, in and out of competition, and it is named again in the 2027 List in force January 1, 2027 [6][7].

Check what you know

Think you have it? Try 3 quick questions and see what the article says.

1. According to the article, does an FDA-approved sermorelin product exist today?

Question 1 of 3

Score: 0 right, 0 of 3 answered

Is there a standard lab schedule for sermorelin?
No. No FDA-approved sermorelin product exists, so there is no label lab section [1]. The 1-year pediatric trial monitored height velocity, bone age progression and safety measures including clinical chemistry every 3 to 6 months [2].
Which labs were reported in sermorelin studies?
The pediatric trial reported no change in fasting glucose and no excessive generation of IGF-I alongside general biochemical and hormonal analyses [2]. The adult study measured IGF-I and 24-hour growth hormone profiles during 14-day dosing [3].
Did sermorelin raise blood sugar in the studies?
In the 1-year pediatric trial, fasting glucose did not change [2].
Is sermorelin FDA-approved today?
No. Geref was discontinued in 2008 and FDA withdrew both approvals in 2009, later determining it was not withdrawn for safety or effectiveness reasons [1]. Compounded sermorelin is not FDA-approved [5].
Can IGF-I results from different labs be compared?
Not necessarily. A 2011 consensus statement found major improvements are needed in assay performance and comparability and recommended a commutable standard for each assay plus age-specific normative data for IGF-I [4].
Show all 9 referencesHide references
  1. Federal Register :: Request Access.
  2. Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. J Clin Endocrinol Metab. 1996;81(3):1189-96.
  3. Corpas E, Harman SM, Piñeyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-5.
  4. Clemmons DR. Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Clin Chem. 2011;57(4):555-9.
  5. Official web page.
  6. World Anti-Doping Agency.
  7. World Anti-Doping Agency.
  8. Reddit participants. Lab work prior (r/USPeptides). Accessed 2026-11-10.
  9. Reddit participants. Sermorelin beginner questions (r/USPeptides). Accessed 2026-11-10.
Sermorelin monitoring schedule: evidence summary chart
Image: HealthRX.com. Full sermorelin monitoring schedule guide and sources at healthrx.com/sermorelin.